MediFind

Find a Doctor

Yoshinori M. Ito

Nagoya University Graduate School Of Medicine
Pediatrics
Male

Bio


Yoshinori Ito is a Pediatrics specialist in Nagoya, Japan. They have been an author on 652 peer reviewed articles in the past 15 years. Dr. Ito's top three areas of expertise are Breast Cancer, Mononucleosis, and HER-2 Positive Breast Cancer.

Contact

Nagoya, 46685, JP

Latest Research


Latest Advance
Study
  • Condition: Congenital Lower Lid Epiblepharon
  • Journal: Annals of plastic surgery
  • Treatment Used: Modified Hotz Procedure Combined with Epicanthoplasty
  • Number of Patients: 60
  • Published —
In this study, researchers evaluated the outcomes of having the modified Hotz procedure combined with epicanthoplasty for the treatment of congenital lower lid epiblepharon.
Latest Advance
Study
  • Condition: HER2-Positive Primary Breast Cancer
  • Journal: Breast cancer research and treatment
  • Treatment Used: Docetaxel?+?Carboplatin?+?Trastuzumab?+?Pertuzumab (TCbHP), TCbHP followed by Trastuzumab Emtansine and Pertuzumab (T-DM1+P), and T-DM1+P
  • Number of Patients: 236
  • Published —
This study compared docetaxel?+?carboplatin?+?trastuzumab?+?pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Latest Advance
Study
  • Condition: Previously Treated HER2-Positive Breast Cancer
  • Journal: The New England journal of medicine
  • Treatment Used: Trastuzumab Deruxtecan
  • Number of Patients: 184
  • Published —
This study evaluated the effectiveness of trastuzumab deruxtecan in patients with previously treated HER2-positive metastatic breast cancer.
Latest Advance
Study
  • Condition: Locally advanced esophageal neuroendocrine carcinoma
  • Journal: Cancer medicine
  • Treatment Used: Chemoradiotherapy
  • Number of Patients: 22
  • Published —
The study researched the effects of chemoradiotherapy (chemo and radiation) for locally advanced esophageal neuroendocrine carcinoma.
Latest Advance
Study
  • Condition: Resectable Advanced Gastric Cancer
  • Journal: The British journal of surgery
  • Treatment Used: Extensive Intraoperative Peritoneal Lavage (EIPL) vs. Standard Treatment
  • Number of Patients: 295
  • Published —
This study tested whether extensive intraoperative peritoneal lavage (EIPL) may reduce peritoneal recurrence in patients with advanced gastric cancer who undergo surgery with curative intent.
Latest Advance
Study
  • Condition: Locally Advanced Unresectable Esophageal Cancer
  • Journal: Annals of surgical oncology
  • Treatment Used: Docetaxel plus 5-Fluorouracil and Cisplatin (DCF) Induction Chemotherapy (ICT)
  • Number of Patients: 0
  • Published —
This study tested the safety and efficacy of using a DCF ICT to treat patients with locally advanced unresectable esophageal cancer.
Latest Advance
Study
  • Condition: Locally Advanced Cervical Cancer
  • Journal: BMC cancer
  • Treatment Used: Intracavitary and Interstitial Brachytherapy
  • Number of Patients: 42
  • Published —
This study tested the safety and efficacy of using an intracavitary and interstitial bracytherapy to treat patients with locally advanced cervical cancer.
Latest Advance
Study
  • Condition: Invasive Breast Cancer
  • Journal: Japanese journal of clinical oncology
  • Treatment Used: hypofractionated whole body irradiation after breast-conserving surgery
  • Number of Patients: 306
  • Published —
The purpose of the study was to evaluate the safety of hypofractionated whole breast irradiation in Japanese women after breast-conserving surgery for invasive breast cancer.
Latest Advance
Study
  • Condition: Non-small-cell lung cancer
  • Journal: Japanese journal of clinical oncology
  • Treatment Used: Stereotactic body radiation therapy
  • Number of Patients: 28
  • Published —
This study evaluated the safety and efficacy of stereotactic body radiation therapy for patients with peripheral T2N0M0 non-small-cell lung cancer.
Latest Advance
Study
  • Condition: Breast cancer
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Buparlisib plus fulvestrant
  • Number of Patients: 2025
  • Published —
This study evaluated the effects of buparlisib plus fulvestrant in postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer.
Latest Advance
Study
  • Condition: Esophageal squamous cell carcinoma
  • Journal: International journal of clinical oncology
  • Treatment Used: Preoperative chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation followed by esophagectomy with radical lymph node dissection
  • Number of Patients: 31
  • Published —
This study evaluated the feasibility of preoperative chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation followed by esophagectomy with radical lymph node dissection in patients with stage II/III esophageal squamous cell carcinoma.
Latest Advance
Study
  • Condition: HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes
  • Journal: Breast (Edinburgh, Scotland)
  • Treatment Used: trastuzumab plus capecitabine versus lapatinib plus capecitabine
  • Number of Patients: 86
  • Published —
The purpose of the study was to compare the effectiveness of trastuzumab plus capecitabine versus lapatinib plus capecitabine for HER2-positive metastatic breast cancer.
Latest Advance
Study
  • Condition: Acute lymphoblastic leukemia (ALL)
  • Journal: Leukemia
  • Treatment Used: High-dose methotrexate (Hd-MTX)
  • Number of Patients: 115
  • Published —
This study evaluated the effectiveness of high-dose methotrexate (Hd-MTX) therapy to treat adult acute lymphoblastic leukemia (ALL). Patients with Philadelphia chromosome (Ph) negative who achieved complete remission (CR) were randomized.
Latest Advance
Study
  • Condition: Pulmonary Complications (PPCs) After Thoracoscopic Esophagectomy
  • Journal: Surgical endoscopy
  • Treatment Used: Laparoscopy
  • Number of Patients: 379
  • Published —
This study determined the impact of laparoscopy on the prevention of postoperative pulmonary complications (PPCs) after thoracoscopic esophagectomy.

Clinical Trials


This doctor has not participated in any recent clinical trials.

Contact

Nagoya, 46685, JP

Insurance

Contact them to find out if they accept your insurance plan.